Form 6-K Wellchange Holdings Co For: Aug 20

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of August 2026

 

Commission File Number: 001-42294

 

Wellchange Holdings Company Limited

 

Unit 7 On 25th Floor, Global Gateway Tower, No. 63 Wing Hong Street,

Kowloon, Hong Kong

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

 

Form 20-F ☒     Form 40-F ☐

 

 

INFORMATION CONTAINED IN THIS FORM 6-K REPORT

 

In connection with (i) a meeting of the holders of class B ordinary shares and (ii) an extraordinary general meeting of shareholders of Wellchange Holdings Company Limited (the “Company”), attached hereto and incorporated by reference herein are the Notice of Extraordinary General Meeting and Proxy Statement, the Form of Proxy Card for the Class B Meeting and the Form of Proxy Card for the Extraordinary General Meeting.

 

 

EXHIBIT INDEX

 

Exhibit No.		Description
99.1		Notice of Extraordinary General Meeting and Proxy Statement
99.2		Form of Proxy Card for the Class B Meeting
99.3		Form of Proxy Card for the Extraordinary General Meeting

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

	Wellchange Holdings Company Limited
Date: August 20, 2026	By:	/s/ Shek Kin Pong
	Name:	Shek Kin Pong
	Title:	Chief Executive Officer

 

 

ATTACHMENTS / EXHIBITS

NOTICE OF EXTRAORDINARY GENERAL MEETING AND PROXY STATEMENT

FORM OF PROXY CARD FOR THE CLASS B MEETING

FORM OF PROXY CARD FOR THE EXTRAORDINARY GENERAL MEETING

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Wellchange Holdings prices $7.5M share offering at $0.15 per share
• Acceleware Ltd. Reports Second Quarter 2026 Financial and Operating Results
• Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera